In our previous article, Introduction to Cannabinoids, we explored the fascinating world of cannabinoids, their origin, and their interaction with the endocannabinoid system (ECS). If you haven’t read it yet, we recommend starting there to get a better understanding of the fundamentals. In this article, we’ll take a deeper dive into some popular types of cannabinoids; discussing their potential benefits. Additionally, we’ll highlight ongoing research on cannabinoids to shed light on the exciting potential these compounds hold.

As we discussed previously, cannabinoids are a diverse group of chemical compounds found in cannabis and hemp plants. These compounds interact with the ECS, a complex signaling system responsible for maintaining homeostasis and regulating various bodily functions. The ECS plays a crucial role in keeping our bodies balanced, impacting mood, pain perception, appetite, immune response, and more.

common types of Cannabinoids:

• Cannabichromene (CBC): CBC is a non-psychoactive cannabinoid that has shown potential anti-inflammatory properties. Research suggests that CBC may also interact with pain receptors, making it a subject of interest in pain management studies.
• Cannabidiol (CBD): CBD has gained widespread attention for its various potential benefits. Although research is ongoing, CBD has been explored for its anxiolytic, anti-inflammatory, and neuroprotective properties. It may also play a role in promoting overall well-being and stress management.
• Cannabidiolic Acid (CBDa): CBDa is the acidic precursor to CBD, and early research indicates potential anti-inflammatory and anti-nausea effects. While CBDa’s potential benefits are intriguing, more studies are needed to fully understand its therapeutic properties.
• Cannabigerol (CBG): CBG has shown promise as an anti-inflammatory agent and may have neuroprotective properties. Like other cannabinoids, ongoing research is needed to uncover CBG’s full range of potential benefits.
• Cannabigerolic Acid (CBGa): CBGa is the precursor to several cannabinoids, including CBG, CBD, and THC. As researchers continue to investigate cannabinoids, CBGa’s potential therapeutic properties are likely to be further explored.
• Cannabinol (CBN): CBN is a product of THC degradation, and while it may have mild psychoactive effects, it is not as potent as THC. Some studies suggest CBN may have potential as a sleep aid, but further research is necessary to confirm its benefits.
• Tetrahydrocannabinol (THC): THC is the primary psychoactive compound in cannabis, responsible for the euphoric “high” associated with marijuana use. Beyond its recreational effects, THC has potential therapeutic benefits, including pain relief and appetite stimulation. However, it is essential to be cautious with THC due to its psychoactive nature.
• Tetrahydrocannabivarin (THCV): THCV is structurally similar to THC but has different effects. Research suggests that THCV may have potential in appetite suppression and weight management. However, as with many cannabinoids, more comprehensive studies are needed to validate these findings.

Potential benefits of various types of cannabinoids and Ongoing Research:

1. Epilepsy and CBD: One area of significant interest is the potential use of CBD in managing certain forms of epilepsy. The US Food and Drug Administration (FDA) has approved Epidiolex, a CBD-based medication, for the treatment of certain rare and severe forms of epilepsy, namely Lennox-Gastaut syndrome and Dravet syndrome. This approval came after rigorous clinical trials and extensive research in this specific context.
2. Pain Management and THC/CBD: Cannabinoids like THC and CBD have been explored for their potential in pain management. Some studies have indicated that these cannabinoids may provide relief for chronic pain conditions. For example, a review published in the Journal of Clinical Pharmacology found evidence suggesting the potential efficacy of cannabinoids in reducing neuropathic pain.
3. Anxiety and CBD: CBD has also garnered attention for its potential anxiolytic effects. Preliminary research has indicated that CBD may help alleviate symptoms of anxiety disorders. However, it is essential to note that more comprehensive and controlled studies are needed to establish the safety and efficacy of CBD as a treatment for anxiety.
4. Anti-Inflammatory Effects: Several cannabinoids, including CBD and CBG, have demonstrated anti-inflammatory properties in preclinical studies. These findings have sparked interest in the potential application of cannabinoids in managing inflammation-related conditions. However, human clinical trials are necessary to validate these effects in real-world scenarios.

It is crucial to recognize that these studies are part of an ongoing and evolving body of research. While these initial findings are promising, further investigation is needed to fully understand the potential benefits and limitations of the different types of cannabinoids in various contexts. Please note that the information provided is for educational and informational purposes only and should not be considered as medical advice. Always consult with a qualified healthcare professional before using cannabinoids or any other supplements for health-related purposes.

In our next blog post, we will delve into the enthralling world of terpenes and explore the entourage effect, where cannabinoids and terpenes work synergistically to enhance their effects. Be sure to join us on this journey as we continue to uncover the wonders of cannabinoids and their potential applications in the realm of health and wellness.

References:

Borrelli, F., Pagano, E., Romano, B., Panzera, S., Maiello, F., Coppola, D., … & Izzo, A. A. (2014). Colon carcinogenesis is inhibited by the TRPM8 antagonist cannabigerol, a Cannabis-derived non-psychotropic cannabinoid. Carcinogenesis, 35(12), 2787-2797.
Di Marzo, V., & Piscitelli, F. (2015). The endocannabinoid system and its modulation by phytocannabinoids. Neurotherapeutics, 12(4), 692-698.
Mechoulam, R., Parker, L. A., & Gallily, R. (2002). Cannabidiol: An overview of some pharmacological aspects. Journal of Clinical Pharmacology, 42(S1), 11S-19S.
Pertwee, R. G. (2008). The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: Δ9-tetrahydrocannabinol, cannabidiol, and Δ9-tetrahydrocannabivarin. British Journal of Pharmacology, 153(2), 199-215.
Hill, A. J., Weston, S. E., Jones, N. A., Smith, I., Bevan, S. A., Williamson, E. M., … & Williams, C. M. (2010). Δ9-Tetrahydrocannabivarin suppresses in vitro epileptiform and in vivo seizure activity in adult rats. Epilepsia, 51(8), 1522-1532.
Devinsky, O., Cross, J. H., Laux, L., Marsh, E., Miller, I., Nabbout, R., … & Wright, S. (2017). Trial of cannabidiol for drug-resistant seizures in the Dravet syndrome. New England Journal of Medicine, 376(21), 2011-2020.
Thiele, E. A., Marsh, E. D., French, J. A., Mazurkiewicz-Beldzinska, M., Benbadis, S. R., Joshi, C., … & Devinsky, O. (2018). Cannabidiol in patients with seizures associated with Lennox-Gastaut syndrome (GWPCARE4): a randomised, double-blind, placebo-controlled phase 3 trial. The Lancet, 391(10125), 1085-1096.
Xiong, W., Cui, T., Cheng, K., Yang, F., Chen, S. R., Willenbring, D., … & Zhang, L. (2012). Cannabinoids suppress inflammatory and neuropathic pain by targeting α3 glycine receptors. Journal of Experimental Medicine, 209(6), 1121-1134.
Blessing, E. M., Steenkamp, M. M., Manzanares, J., & Marmar, C. R. (2015). Cannabidiol as a potential treatment for anxiety disorders. Neurotherapeutics, 12(4), 825-836.